Woo Jin Jang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Woo Jin Jang has a total of 188 co-authors. Here are the top co-authors by number of shared publications:
- Hyeon-Cheol Gwon
Division of Cardiology, Department of Medicine, Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
16 shared publications - Jin-Ok Jeong
Chungnam National University Hospital, Chungnam National University College of Medicine, Daejeon, Korea
16 shared publications - Jeong Hoon Yang
Division of Cardiology, Department of Medicine, Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
15 shared publications Hyeon-Cheol Gwon
Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
13 shared publicationsIk Hyun Park
Department of Cardiology, Department of Internal Medicine, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Republic of Korea
12 shared publicationsJeong Hoon Yang
Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
11 shared publications
Latest Publications
- Open Access
- 2 November 2026
- Published by Springer Nature in Scientific Reports
Association of admission acid-base phenotypes with delirium in cardiac critical illness: a multicenter cohort study
- 2 November 2026
- Published by Springer Nature in Scientific Reports
Open AccessAssociation of admission acid-base phenotypes with delirium in cardiac critical illness: a multicenter cohort study
- Open Access
- 13 October 2026
- Published by Wolters Kluwer Health in ASAIO Journal
Forty-Eight Hour Lactate Normalization Predicts Favorable Neurologic Recovery and Survival in Venoarterial ECMO for Cardiogenic Shock
Extracorporeal membrane oxygenation (ECMO) for cardiogenic shock (CS) is associated with high mortality and poor neurological outcomes. Dynamic assessment of metabolic recovery, reflected by lactate normalization, may offer additional prognostic value compared with static severity indices. We retrospectively analyzed 662 consecutive patients from the multicenter RESCUE II registry who remained on venoarterial ECMO for at least 48 hours. Patients were stratified by 48 hour lactate level: 48 hour lactate normalization group (< 2.0 mmol/L, n = 371) and persistent lactate elevation group (≥ 2.0 mmol/L, n = 291). The primary outcome was favorable neurologic discharge (FND), defined as discharge with a Cerebral Performance Category score of 1 or 2. The persistent lactate elevation group had a higher SOFA score (9.8 ± 3.2 vs . 8.5 ± 3.4, p < 0.001) and initial serum lactate (7.9 ± 4.8 mmol/L vs. 6.0 ± 4.3 mmol/L, p < 0.001). Lactate normalization was associated with a higher rate of FND (71.4% vs . 41.9%, p < 0.001), remained an independent predictor of FND (odds ratio [OR]: 3.12, 95% confidence interval [CI]: 2.21–4.41, p < 0.001), and was associated with lower risks of all-cause death (hazard ratio [HR]: 0.49, 95% CI: 0.38–0.64, p < 0.001) at 12 months. In conclusion, lactate normalization within 48 hours of ECMO initiation is associated with favorable neurologic status and 12 month survival.
- 13 October 2026
- Published by Wolters Kluwer Health in ASAIO Journal
Open AccessForty-Eight Hour Lactate Normalization Predicts Favorable Neurologic Recovery and Survival in Venoarterial ECMO for Cardiogenic Shock
Extracorporeal membrane oxygenation (ECMO) for cardiogenic shock (CS) is associated with high mortality and poor neurological outcomes. Dynamic assessment of metabolic recovery, reflected by lactate normalization, may offer additional prognostic value compared with static severity indices. We retrospectively analyzed 662 consecutive patients from the multicenter RESCUE II registry who remained on venoarterial ECMO for at least 48 hours. Patients were stratified by 48 hour lactate level: 48 hour lactate normalization group (< 2.0 mmol/L, n = 371) and persistent lactate elevation group (≥ 2.0 mmol/L, n = 291). The primary outcome was favorable neurologic discharge (FND), defined as discharge with a Cerebral Performance Category score of 1 or 2. The persistent lactate elevation group had a higher SOFA score (9.8 ± 3.2 vs . 8.5 ± 3.4, p < 0.001) and initial serum lactate (7.9 ± 4.8 mmol/L vs. 6.0 ± 4.3 mmol/L, p < 0.001). Lactate normalization was associated with a higher rate of FND (71.4% vs . 41.9%, p < 0.001), remained an independent predictor of FND (odds ratio [OR]: 3.12, 95% confidence interval [CI]: 2.21–4.41, p < 0.001), and was associated with lower risks of all-cause death (hazard ratio [HR]: 0.49, 95% CI: 0.38–0.64, p < 0.001) at 12 months. In conclusion, lactate normalization within 48 hours of ECMO initiation is associated with favorable neurologic status and 12 month survival.
- Open Access
- 31 August 2026
- Published by The Korean Society of Critical Care Medicine in Acute and Critical Care
- Vol. 41 (3) , 506-514
Venoarterial extracorporeal membrane oxygenation as a rescue strategy in high-risk pulmonary thromboembolism
Acute high-risk pulmonary thromboembolism (PTE) is the most severe clinical manifestation of venous thromboembolism, carrying a substantial mortality rate, particularly when complicated by cardiogenic shock or cardiac arrest. Although current guidelines recommend systemic thrombolysis for high-risk PTE in the absence of contraindications, this approach is associated with a significant risk of major hemorrhage and may be precluded in patients with severe comorbidities, advanced frailty, or elevated perioperative risk. Consequently, venoarterial extracorporeal membrane oxygenation (VA-ECMO) has emerged as an important mechanical circulatory support strategy for this vulnerable cohort. By bypassing the obstructed pulmonary vascular bed, VA-ECMO facilitates rapid hemodynamic stabilization, mechanically unloads the strained right ventricle, and reverses systemic hypoperfusion. This review elucidates the pathophysiological rationale for right ventricular unloading in high-risk PTE and examines the evolving approach toward catheter-directed interventions and patient-tailored treatment strategies. Furthermore, we evaluate the clinical outcomes of VA-ECMO when deployed either as a stand-alone therapy bridge to recovery alongside systemic anticoagulation or as a bridge to definitive active thrombus clearance.
- 31 August 2026
- Published by The Korean Society of Critical Care Medicine in Acute and Critical Care
- Vol. 41 (3) , 506-514
Open AccessVenoarterial extracorporeal membrane oxygenation as a rescue strategy in high-risk pulmonary thromboembolism
Acute high-risk pulmonary thromboembolism (PTE) is the most severe clinical manifestation of venous thromboembolism, carrying a substantial mortality rate, particularly when complicated by cardiogenic shock or cardiac arrest. Although current guidelines recommend systemic thrombolysis for high-risk PTE in the absence of contraindications, this approach is associated with a significant risk of major hemorrhage and may be precluded in patients with severe comorbidities, advanced frailty, or elevated perioperative risk. Consequently, venoarterial extracorporeal membrane oxygenation (VA-ECMO) has emerged as an important mechanical circulatory support strategy for this vulnerable cohort. By bypassing the obstructed pulmonary vascular bed, VA-ECMO facilitates rapid hemodynamic stabilization, mechanically unloads the strained right ventricle, and reverses systemic hypoperfusion. This review elucidates the pathophysiological rationale for right ventricular unloading in high-risk PTE and examines the evolving approach toward catheter-directed interventions and patient-tailored treatment strategies. Furthermore, we evaluate the clinical outcomes of VA-ECMO when deployed either as a stand-alone therapy bridge to recovery alongside systemic anticoagulation or as a bridge to definitive active thrombus clearance.
- Top Cited Papers
Intravascular Imaging- vs Angiography-Guided Complex PCI
- Open Access
- 28 January 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (3) , 1046
Early Intra-Aortic Balloon Pump Support and In-Hospital Mortality in Patients with LV Dysfunction and Cardiogenic Shock Complicating AMI
Background: Despite advancements in mechanical support (MCS) devices, the mortality rate for patients with cardiogenic shock remains high. This study aimed to evaluate the efficacy of early intra-aortic balloon pump (IABP) support compared to medical therapy in patients with cardiogenic shock (CS) due to acute myocardial infarction (AMI) (AMI-CS) resulting in severe left ventricular (LV) systolic dysfunction. Methods: We analyzed the RESCUE I registry (NCT02985008), a multicenter cohort of 1247 cardiogenic shock patients. A total of 192 patients with AMI-CS with LVEF ≤ 35% received either medical therapy (n = 105) or IABP support (n = 87) after shock development. The primary outcome was in-hospital mortality. Then, we compared mortality in early IABP initiation (shock-to-IABP < 2 h) to medical therapy. Results: The overall in-hospital mortality rate was 42.2%. While the difference in mortality rates between the medical therapy group and the IABP group was not statistically significant (47.6% vs. 35.6%, respectively, p = 0.094), a reduction in mortality was observed when IABP support was initiated within 2 h of shock onset (32.0% vs. 47.6%, p = 0.036). Furthermore, the need for advanced MCS was reduced in the IABP group compared to the medical group (4.6% vs. 22.9%, respectively, p < 0.001). Conclusions: In patients with AMI-CS and severe LV dysfunction, early IABP support initiated within 2 h of shock onset was associated with lower in-hospital mortality and reduced need for advanced MCS. These findings highlight the critical importance of timing rather than routine use, supporting a selective strategy for early IABP.
- 28 January 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (3) , 1046
Open AccessEarly Intra-Aortic Balloon Pump Support and In-Hospital Mortality in Patients with LV Dysfunction and Cardiogenic Shock Complicating AMI
Background: Despite advancements in mechanical support (MCS) devices, the mortality rate for patients with cardiogenic shock remains high. This study aimed to evaluate the efficacy of early intra-aortic balloon pump (IABP) support compared to medical therapy in patients with cardiogenic shock (CS) due to acute myocardial infarction (AMI) (AMI-CS) resulting in severe left ventricular (LV) systolic dysfunction. Methods: We analyzed the RESCUE I registry (NCT02985008), a multicenter cohort of 1247 cardiogenic shock patients. A total of 192 patients with AMI-CS with LVEF ≤ 35% received either medical therapy (n = 105) or IABP support (n = 87) after shock development. The primary outcome was in-hospital mortality. Then, we compared mortality in early IABP initiation (shock-to-IABP < 2 h) to medical therapy. Results: The overall in-hospital mortality rate was 42.2%. While the difference in mortality rates between the medical therapy group and the IABP group was not statistically significant (47.6% vs. 35.6%, respectively, p = 0.094), a reduction in mortality was observed when IABP support was initiated within 2 h of shock onset (32.0% vs. 47.6%, p = 0.036). Furthermore, the need for advanced MCS was reduced in the IABP group compared to the medical group (4.6% vs. 22.9%, respectively, p < 0.001). Conclusions: In patients with AMI-CS and severe LV dysfunction, early IABP support initiated within 2 h of shock onset was associated with lower in-hospital mortality and reduced need for advanced MCS. These findings highlight the critical importance of timing rather than routine use, supporting a selective strategy for early IABP.
- Open Access
- 28 January 2025
- Published by Elsevier in JACC: Asia
- Vol. 5 (3) , 390-392
Optimal Mechanical Circulatory Support Timing in Patients With Acute Myocardial Infarction With Cardiogenic Shock
- 28 January 2025
- Published by Elsevier in JACC: Asia
- Vol. 5 (3) , 390-392
Open AccessOptimal Mechanical Circulatory Support Timing in Patients With Acute Myocardial Infarction With Cardiogenic Shock
- Open Access
- 1 January 2025
- Published by XMLink in Korean Circulation Journal
- Vol. 55 (9) , 795-809
Sex-Specific Differences in Management and Outcomes of Cardiogenic Shock Patients With and Without Ischemic Cardiomyopathy
Park IH, et al. Korean Circ J. 2025 May;55:e86. https://doi.org/10.4070/kcj.2024.0440
- 1 January 2025
- Published by XMLink in Korean Circulation Journal
- Vol. 55 (9) , 795-809
Open AccessSex-Specific Differences in Management and Outcomes of Cardiogenic Shock Patients With and Without Ischemic Cardiomyopathy
Park IH, et al. Korean Circ J. 2025 May;55:e86. https://doi.org/10.4070/kcj.2024.0440
- Open Access
Discontinuation of β-blocker therapy in stabilised patients after acute myocardial infarction (SMART-DECISION): rationale and design of the randomised controlled trial
Introduction There is a lack of evidence to support the effectiveness of prolonged β-blocker therapy after stabilisation of patients with acute myocardial infarction (AMI) without heart failure (HF) or left ventricular systolic dysfunction. Methods and analysis The SMart Angioplasty Research Team: DEcision on Medical Therapy in Patients with Coronary Artery DIsease or Structural Heart Disease Undergoing InterventiON (SMART-DECISION) trial is a multicentre, prospective, open-label, randomised, non-inferiority trial designed to determine whether discontinuing β-blocker therapy after ≥1 year of maintenance in stabilised patients after AMI is non-inferior to continuing it. Patients eligible for participation are those without HF or left ventricular systolic dysfunction (ejection fraction >40%) who have been continuing β-blocker therapy for ≥1 year after AMI. A total of 2540 patients will be randomised 1:1 to continuation of β-blocker therapy or not. Randomisation will be stratified according to the type of AMI (ie, ST-segment-elevation MI or non-ST-segment-elevation MI), type of β-blocker (carvedilol, bisoprolol, nebivolol or other) and participating centre. The primary study endpoint is a composite of all-cause death, MI and hospitalisation for HF over a median follow-up period of 3.5 years (minimum, 2.5 years; maximum, 4.5 years). Adverse effects related to β-blocker therapy, the occurrence of atrial fibrillation, medical costs and Patient-reported Outcomes Measurement Information system-29 questionnaire responses will also be collected as secondary endpoints. Ethics and dissemination Ethics approval for this study was granted by the Institutional Review Board of Samsung Medical Center (no. 2020-10-176). Informed consent is obtained from every participant before randomisation. The results of this study will be submitted for publication in international peer-reviewed journals and the key findings will be presented at international scientific conferences. Trial registration number ClinicalTrials.gov, NCT04769362.
Open AccessDiscontinuation of β-blocker therapy in stabilised patients after acute myocardial infarction (SMART-DECISION): rationale and design of the randomised controlled trial
Introduction There is a lack of evidence to support the effectiveness of prolonged β-blocker therapy after stabilisation of patients with acute myocardial infarction (AMI) without heart failure (HF) or left ventricular systolic dysfunction. Methods and analysis The SMart Angioplasty Research Team: DEcision on Medical Therapy in Patients with Coronary Artery DIsease or Structural Heart Disease Undergoing InterventiON (SMART-DECISION) trial is a multicentre, prospective, open-label, randomised, non-inferiority trial designed to determine whether discontinuing β-blocker therapy after ≥1 year of maintenance in stabilised patients after AMI is non-inferior to continuing it. Patients eligible for participation are those without HF or left ventricular systolic dysfunction (ejection fraction >40%) who have been continuing β-blocker therapy for ≥1 year after AMI. A total of 2540 patients will be randomised 1:1 to continuation of β-blocker therapy or not. Randomisation will be stratified according to the type of AMI (ie, ST-segment-elevation MI or non-ST-segment-elevation MI), type of β-blocker (carvedilol, bisoprolol, nebivolol or other) and participating centre. The primary study endpoint is a composite of all-cause death, MI and hospitalisation for HF over a median follow-up period of 3.5 years (minimum, 2.5 years; maximum, 4.5 years). Adverse effects related to β-blocker therapy, the occurrence of atrial fibrillation, medical costs and Patient-reported Outcomes Measurement Information system-29 questionnaire responses will also be collected as secondary endpoints. Ethics and dissemination Ethics approval for this study was granted by the Institutional Review Board of Samsung Medical Center (no. 2020-10-176). Informed consent is obtained from every participant before randomisation. The results of this study will be submitted for publication in international peer-reviewed journals and the key findings will be presented at international scientific conferences. Trial registration number ClinicalTrials.gov, NCT04769362.
- 27 May 2024
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 17 (10) , 1231-1243
Impact of Intravascular Imaging-Guided Stent Optimization According to Clinical Presentation in Patients Undergoing Complex PCI
- 27 May 2024
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 17 (10) , 1231-1243
Impact of Intravascular Imaging-Guided Stent Optimization According to Clinical Presentation in Patients Undergoing Complex PCI